Document is current
Any future updates will be listed below
-
Authors
Laforêt, Pascal
Inoue, Michio
Goillot, Evelyne
Lefeuvre, Claire
Cagin, Umut
Streichenberger, Nathalie
Leonard-Louis, Sarah
Brochier, Guy
Madelaine, Angeline
Labasse, Clemence
Hedberg-Oldfors, Carola
Krag, Thomas
Jauze, Louisa
Fabregue, Julien
Labrune, Philippe
Milisenda, Jose
Nadaj-Pakleza, Aleksandra
Sacconi, Sabrina
Mingozzi, Federico
Ronzitti, Giuseppe
Petit, François
Schoser, Benedikt
Oldfors, Anders
Vissing, John
Romero, Norma B.
Nishino, Ichizo
Malfatti, Edoardo https://orcid.org/0000-0001-7871-8600
-
Funding
Funding for this research was provided by:
AFM-Téléthon
Agence Nationale de la Recherche (ANR-17-CE18-0014)
Association Francophone des Glycogénoses
- License Information
-
More Information
Article History
Received: 24 July 2019
Accepted: 22 September 2019
First Online: 28 October 2019
Ethics approval and consent to participate
: We confirm that we have read the Journal’s position on issues involved in ethical publication and affirm that this report is consistent with those guidelines. All patients gave informed consent prior to having a muscle biopsy performed.
: G.R. and F.M. are inventors in patents related to the development of gene therapy strategies for GSDIII. All other authors declare no conflicts of interest.
